granisetron oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   5 Trials   5 Trials   76 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
granisetron oral / Generic mfg.
2011-006206-27: Does genetic variance in the serotonergic system contribute to pain and the efficacy of drug that blocks serotonin?

Ongoing
4
70
Europe
Granisetron, Injection, Kytril
Karolinska Institutet, Karolinska Institutet
Experimentally induced muscle pain in healthy volunteers, both sexes and over 18 years of age., Experimentally induced muscle pain in healthy volunteers, both sexes and over 18 years of age., Body processes [G] - Biological Phenomena [G16]
 
 
2006-000755-18: Estudio Fase IV, Nacional, Multicéntrico, competitivo, aleatorizado, doble ciego, controlado de grupos paralelos, para determinar la seguridad, tolerabilidad, y eficacia de aprepitant, más palonosetrón frente a granisetrón en la prevención de las náuseas y la emesis inducidas por quimioterapia en pacientes tratados con trasplante de progenitores hematopoyéticos.

Ongoing
4
196
Europe
EMEND, Aloxi, Kytril, EMEND, Aloxi, Kytril
Fundación PETHEMA
náuseas y vómitos producidos en pacientes tratados con quimioterapia previa al transplante de progenitores hematopoyéticos
 
 
2008-000746-32: Validation of experimental pain models as translational for craniofacial myalgia with respect to the influence of 5-HT, glutamate, cortisol and estradiol level

Ongoing
4
240
Europe
Kytril, Ketalar, Kytril, Ketalar
Karolinska Institutet
Patients with craniomandibular myalgia (CM), i.e. with pain in the masster muscle and a diagnosis of myofascial pain according to the RDC/TMD criteria, and healthy subjects of both sexes, over 18 years of age are included.
 
 
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
NCT03817970: Cisplatin Disposition and Kidney Injury

Active, not recruiting
3
72
US
Granisetron, Kytril, Ondansetron, Zofran, Palonosetron, Aloxi
University of Colorado, Denver, Memorial Sloan Kettering Cancer Center, Rutgers University, National Institute of General Medical Sciences (NIGMS)
Nephrotoxicity
09/25
12/26
2013-000026-57: Does local adminstration of the drug granisetron influence facial skin sensitivity?

Ongoing
2
30
Europe
Kytril, Xylocain, Kytril, Xylocain
Karolinska Institutet, Karolinska Institutet
Healthy and pain-free volunteers > 20 years of age, both sexes
 
 
NCT06175806: Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group

Completed
N/A
160
RoW
Ondansetron Oral Film, Granisetron Oral Liquid Product
Ain Shams University
Nausea and Vomiting in Pediatric Age Group
11/23
11/23

Download Options